Pancreatic cancer has a very poor prognosis. Current chemotherapy and radiotherapy regimens are only moderately successful. The tumour suppressor genes p53 and p16
Introduction
Pancreatic cancer has a very poor prognosis with an overall 5 year survival of 0.4% 1 and is responsible for 7000 deaths per year in the UK 2 and 28 000 per year in the USA. 3 The majority of patients who present have advanced disease and are not suitable for potentially curative resection. Currently available chemotherapy regimens are undergoing assessment in the adjuvant setting but are not consistently effective in those patients with advanced disease. 4 Novel methods of treatment, which take advantage of molecular mechanisms in cancer, are needed to improve the overall outlook for these patients. The tumour suppressor genes p53 and p16 are frequently mutated with loss of function in pancreatic cancer. Up to 80% of cancers have no detectable p16 protein 5, 6 due to homozygous deletion, mutation or promoter methylation. p53 is present in a mutated form in up to 60% of pancreatic cancers. 7, 8 p53 functions in a variety of pathways to control the G1/S phase of the cell cycle and initiate repair of damaged DNA or induce apoptosis. Many of the actions of p53 can be attributed to its ability to sense DNA damage and induce the tran-lar control viruses expressing either luciferase or ␤-galactosidase. G1 arrest was observed in all cell lines 72 h after infection with Adp16. Infection with Adp53 caused significant levels of apoptosis (P Ͻ 0.004). Apoptosis was also observed to a lesser degree (P Ͻ 0.03) with the Adp16 vector. Subcutaneous pancreatic tumours, generated in nu-nu mice demonstrated significant growth suppression following injection of Adp53, Adp16 and a combination of both Adp53 and Adp16 (P Ͻ 0.0001). These results show that transfer of wild-type p53 and p16 produces significant growth suppression of pancreatic cancer in vitro and in vivo. Gene Therapy (2001) 8, 199-208. scription of a number of genes. 9 G1 arrest is mediated in part by p53 induction of p21, a universal cyclin-dependent kinase (CDK) inhibitor. 10, 11 p16 belongs to the INK4 class of cyclin-dependent kinase inhibitors (CKIs) including p15, p18 and p19 which specifically inhibit cyclinD1/CDK4 or CDK6 complexes. 12 CDKs are responsible for the phosphorylation of the retinoblastoma protein (pRb) and pRb-related proteins. Once phosphorylated, pRb releases the E2F family of transcription factors resulting in activation of genes required for S phase entry. 13 Thus by binding to and inhibiting CDK4/6, p16 prevents both pRb phosphorylation and subsequent progression into the S phase of the cell cycle. The key role of p16 has been confirmed in studies of transgenic mice with targeted p16 mutations, which demonstrate that these animals tend to develop spontaneous tumours at an early age. 14 Previous work has shown the antitumour effects of both p16 and p53 in a variety of human tumours. [15] [16] [17] [18] [19] In the present study we show that adenovirus-mediated transfer of p16 and p53 to pancreatic cancer cells results in tumour regression both in vitro and in vivo.
Results
Gene transfer efficiency and transgene expression in vitro In order to determine the titre of adenoviral vector required for efficient gene transfer into pancreatic adeno-carcinoma cell lines, five such cell lines were infected with AdlacZ and subsequently examined for blue staining following X-gal treatment. There was variation in transduction efficiency between the cell lines tested. A multiplicity of infection (MOI) of 50 resulted in 90% of cells staining blue in the case of Capan2, BxPc3 and Panc1 cells. A higher MOI (100) was required to obtain this level of transduction in CFPAC1 and MIAPACA2 cells. These MOIs were used in all subsequent experiments.
Transgene expression was examined by Western analysis (Figure 1a, b) . All of the cell lines used are p16 null with the exception of CFPAC1, which contains a wildtype locus for the gene. Accordingly, following infection with the control AdlacZ virus, p16 was detected only in CFPAC1 cells (Figure 1ai , lane 5). Infection with the Adp16 vector gave rise to detectable p16 in all cell lines and increased p16 levels in CFPAC1 (Figure 1aii) . All of the cell lines, with the exception of Capan2, contain mutated p53. Western analysis was carried out to examine p53 expression following infection with the Adp53 vector. The antibody used reacts with both wild-type and mutant p53. Consistent with this, p53 was detected in each cell line following infection with AdlacZ ( Figure  1bi ). The quantity of p53 was increased following infection with Adp53 ( Figure 1bii ). Immunofluorescence was used to confirm the transfer of wild-type p53 and p16 into the cells (Figure 2a, b) . The antibody against p53 protein (DO7, DAKO Ltd, Cambridgeshire, UK) is active against both wild-type and mutant p53. Nuclear staining was demonstrated in the cell lines with mutated p53, except in CFPAC1. In this cell line the pattern of staining was cytoplasmic but following p53 infection there was predominantly nuclear immunofluorescence ( Figure 2a (Figure 3a-e) . Taking all cell lines together, mock-infected cells were shown to grow from 1-5 × 10 5 at time zero to 3-8 × 10
6 by day 7. There was significant growth inhibition following treatment with Adp16, Adp53 and a combination of these, compared with the control virus or mock infection with PBS for all cell lines (P Ͻ 0.002) (Figure 3a-e) . Infection with the control vector Adluc had a small, though reproducible effect on cell growth and was most pronounced for the cell line CFPAC1. When the use of Adp16 and Adp53 alone was compared with both together, there was a trend towards increased growth reduction with the combination but this did not reach significance ( Table 1) .
Overexpression of p53 and p16 induce cell cycle arrest in pancreatic adenocarcinoma cell lines Time-course flow cytometry was performed on cells following infection with AdlacZ, Adp16 or Adp53. Seventytwo hours after infection the proportion of cells in the G1 phase of the cell cycle, for all cells examined, was significantly higher in the Adp16 infected cells than in the control vector infected cells (Figure 4 ). Following infection with AdlacZ the profiles are indistinguishable from uninfected cells with the cell lines in Figure 4 . Following infection with Adp53 there is a shift to the left with a higher percentage of cells in G1 phase of the cell cycle. There is also a higher percentage of cells in the pre-G1 peak. Following infection with Adp16 the majority of cells are in the G1 phase of the cell cycle in all cell lines including CFPAC1 which is wild type for p16. This was reflected in the G1/S ratio, following infection by Adp16 and AdlacZ for each cell line, which was 7.5 and 3.2 for BxPc3, 8.3 and 1.4 for Panc1, 6.3 and 1.6 for MIAPACA2, 11.2 and 2.7 for Capan2 and 7.0 and 0.8 for CFPAC1, respectively (P Ͻ 0.03). Accumulation of cells in the G1/G0 phase correlated with a reduction of the proportion of cells in the S phase in all cell lines following Adp16 infection. Following infection with Adp53 there was a shift to the left with a proportion of cells arresting in G1 (much less than that seen with Adp16), but with a larger proportion in the pre-G1 peak, indicating apoptosis.
The pre-G1 peak was examined in more detail in BxPC3 cells at 48 and 72 h. There was an increase in the pre-G1 peak (indicating apoptotic cells) following infection with Adp16 at 48 and 72 h. There is also an increase in the pre-G1 peak following infection with Adp53 at 48 and 72 h. The most pronounced effect is seen at 72 h with a combination of Adp53 and Adp16 infection in which over 90% of cells were in the pre-G1 peak (Table 2) . This was true of all other cell lines examined (not shown). The proportion of cells undergoing apoptosis was scored for each cell line and each vector (Table 3 ). Both therapeutic vectors produced significantly more apoptotic cells than the control vectors (P Ͻ 0.004 for Adp53 and P Ͻ 0.03 for Adp16).
TdT labelling
In vivo studies Subcutaneous MIAPACA2 tumours generated in 8-weekold female nu-nu mice were treated by injection with adenoviral vectors (see Methods). Twenty-four hours following the last injection, tumours from one mouse of each group were removed and transgene expression confirmed (Figure 6a , b) for both the Adp53 and Adp16 viruses. Tumour volumes were measured regularly during 21 days following treatment. After 21 days there was a significant difference in tumour volume between the Adp53 group, the Adp16 group or the group which received both virus groups, when compared with the control vector groups (P Ͻ 0.0001) (Figure 7a ). There was significant tumour regression following treatment with Gene Therapy either Adp16, Adp53 or a combination of both compared with AdlacZ or Adluc. Because of variability of the initial tumour volume between animals, the ratio of tumour volume change was calculated for each tumour. Mean (standard deviation) ratio of change was 3.9 (2.7) for Adluc, 2.3 (0.9) for AdlacZ, 1.4 (1.6) for Adp16, 1.5 (1.6) for Adp53 and 1.1 (1.1) for Adp16 + Adp53. The ratio of tumour volume change was significantly lower for those animals treated with Adp16, Adp53 or a combination of both compared with those treated with AdlacZ or Adluc, indicating suppression of tumour growth. There was no significant difference in tumour growth rate between the Adp16, Adp53 or combination groups. There was also no significant difference in tumour growth rate between the two control virus groups, AdlacZ and Adluc. There was continued growth arrest of the Adp16-and Adp53-treated tumours observed to 52 days following which there was a gradual increase in tumour volume (Figure 7b ). The AdlacZ control virus appeared to have some antitumour growth effect compared with the Adluc control virus but this was not statistically significant. Survival analyses were carried out on the animals in treatment groups Adp53, Adp16, Adluc and AdlacZ. There was a significant difference in survival between the animals in the Adp53 group and those in Adluc group (P Ͻ 0.05). There was no significant difference in survival between the other treatment groups.
Discussion
Tumour suppressor gene therapy has been used for a variety of human cancers and in early clinical studies of head and neck cancer and lung cancer. [14] [15] [16] [17] [18] [19] [20] In experimental pancreatic cancer, introduction of the p53 gene p53 and p16 gene therapy in pancreatic cancer P Ghaneh et al 203 has been shown to induce cell death in vitro and slow tumour progression in vivo 21 in a variety of pancreatic cancer cell lines. Recently, an adenoviral vector expressing p16 was used to suppress growth in the MIAPACA2 pancreatic cancer cell line. 15 In this study, we have used a panel of human pancreatic cancer cell lines with well characterised defects in p53 and p16 genes to identify differences following treatment with the Adp16 and Adp53 vectors used. It is relatively rare to find mutated Rb in pancreatic cancer 22 and the cell lines used in this study all had wild-type Rb. p16 gene therapy should require a functional Rb pathway to produce G1 arrest and growth inhibition. This however, may not be essential as there is 
(a) demonstrates a 294 bp band in the Adp53-treated tumour (T) and none in the control-treated tumour (C). (b) demonstrates 390 bp bands in the Adp16-treated tumour (T) and none in the control virus-treated tissue (C). P, positive control (vector DNA); N, negative control (RT minus control).
some evidence that in cancer cells with non-functional pRb, overexpression of p16 can produce growth inhibition without associated G1 arrest. 23 The importance of p16-induced cell cycle arrest has been shown in studies demonstrating that it is long-term expression of p16 and not constitutively active pRb that leads to sustained G1 arrest. 24 Two different MOIs were used in this study to achieve equivalent rates of transduction for the different cell lines. Differences in transduction efficiency of the cell lines may relate to the expression of ␤3 integrins and coxsackievirus and adenovirus receptor (CAR) on tumour cells. 25 Following the transfer of wild-type p53 into tumour cells there was a significant inhibition of population
Figure 7 Tumour volume growth curves. (a) demonstrates mean (± s.e.m.) tumour volume curves for subcutaneous tumours generated by MIAPACA2 cells in nu-nu mice for 21 days following injection of virus. (n = 6 animals or 12 tumours for each of the five groups.) All five treatment groups are represented on this chart. There was significant growth suppression of all the Adp53, Adp16 and Adp53 + Adp16-treated tumours compared with the control viruses by 21 days (P Ͻ 0.0001 ANOVA). (b) demonstrates mean (± s.e.m.) tumour growth curves over a period of 52 days following infection with virus vectors, during the time period 21 to 52 days the mean tumour volumes include less than the six animals (12 tumours) as certain animals had to be killed during the experiment according to protocol. The chart shows the tumour volumes for groups 1, 2, 3 and 4 and includes the tumour volumes at 21 days following virus injection, shown in (a).
growth. This was observed particularly in vitro, in all the cell lines. All the cell lines used express mutated p53 protein with the exception of Capan2 that has wild-type p53. Infection with Adp53 produced growth suppression in this cell line also. Infection with Adp53 was associated with marked apoptosis in all cell lines, in particular the cell line Capan2. Infection of Adp53 also induced apoptosis in Hep 2 cells (human laryngeal cancer cell line) and an SV40-transformed human fibroblast cell line, both of which contain wild-type p53 (data not shown). Previous studies have reported that endogenous wildtype p53 protects against apoptosis induced by forced p53 expression, for example the expression of endogenous wild-type p53 in glioma cells appears to protect against p53 transfer-associated apoptosis. 26 Overexpression of p53 in NP-29 (a pancreatic cancer cell line with wild-type p53) did not induce apoptosis in a recent study. 27 However, our results are similar to studies in ovarian cancer cell lines in which endogenous p53 status does not protect cells from apoptosis due to p53 replacement therapy. 28 The majority of cells was apoptotic by 72 h and FACS analysis revealed that there was no significant increase in the G1/S ratio associated with transfer of Adp53.
Adp16 infection produced significant tumour growth suppression, associated with significant G1 arrest in all cell lines, including CFPAC1which has wild-type p16. The G1 arrest observed with Adp16 infection was abolished when using both the Adp16 and the Adp53 vectors.
Gene Therapy
The transfer of p16 was associated with a moderate level of apoptosis as shown by TUNEL assay and FACS analysis. This has been observed previously in lung, ovarian and cervival cancer cell lines. 29, 30 The precise mechanism by which p16 induces apoptosis is unclear, but its overexpression could induce aberrant differentiation processes associated with G1 arrest contributing to a cellular response to undergo apoptosis. 29 In cell lines with mutated p16 and therefore a disruption in the p16/Rb/E2F regulatory pathway, there is deregulation of E2F transcription factors. E2F can act as a tumour suppressor gene, as shown by the development of spontaneous tumours in E2F-1−/− transgenic mice, 31 and can induce apoptosis in a p53-independent manner. 32 Since four of the cell lines had mutated p53 the mechanism underlying the p16-associated apoptosis must be p53-independent and deserves further study. The combination of both Adp16 and Adp53 infection produced high levels of apoptosis as indicated using TdT labelling and FACS analysis. Previous work in ovarian cancer cells has shown that overexpression of both p16 and p53 resulted in regression of tumour. In this study, apoptosis was observed only with a combination of p53 and p16. 33 In our study p16 and p53 were equally effective alone in tumour cell killing (Table 1 ), although the rates of apoptosis are less for p16-treated tumours (Table 2 ) and the combination of both did not show increased cell growth inhibition in vitro. Consistent with this, a combination of both was shown not to be more effective than the single vector in controlling tumour growth. This system of adenovirus-mediated transfer of wild-type p53 and p16 was then used to treat subcutaneous pancreatic tumours in nude mice. The growth rate of these tumours in mice is slow. Three injections were given on consecutive days to maximise the dosage. After 24 h following the last injection it was possible to detect the transgene in the tumours. There was significant tumour growth suppression following infection with Adp53, Adp16 and a combination of both compared with control viruses. The effects of the therapeutic transgene were significantly greater than the control viruses. Growth suppression was seen at 52 days (although this was less than that seen earlier) and this prolonged effect was encouraging considering that no further virus injections were given beyond the initial treatment and the main mechanism for Adp16 activity was growth arrest. There was little additional benefit from the use of both Adp53 and Adp16. The optimum method of administration may be to inject Adp53 then follow this with Adp16 at a later time-point. p16 induces cell cycle arrest and therefore these cells may be resistant to the effects of wild-type p53 at that time. By using p53 first, those cells that have escaped apoptosis may still be sensitive to p16-mediated cell cycle arrest, if p16 is administered later. The rate of gene transduction was 5% to 15% using immunohistochemistry analysis for p16 (Figure 8) . Poor spread within a tumour is, however, well documented and is an issue for adenoviral gene therapy (and all direct injection gene therapy) and is an area of active research. Therefore, incomplete transduction is probably at least partially responsible for incomplete regression.
Clinically, the use of repeated intratumoral injections should ensure good transgene expression. 34 Second generation adenoviruses with further deletion of immunogenic sequences may increase efficacy 35 although pre- existing immunity to adenovirus may not prevent tumour regression but limit virus dissemination. 36 There is some evidence that even with a robust immune response there may still persist biodistribution of adenovirus for a long period. 18 It must be noted, however, that early phase I and II clinical trials of the E1-deleted adenovirus ONYX 015 in patients with advanced pancreatic cancer have not been encouraging with no response seen in these tumours following treatment (D Kirn, personal communication). There are unique difficulties associated with this approach for pancreatic cancer. The primary tumour may be difficult to approach for percutaneous injection and isolated perfusion is a technically demanding procedure. Subcutaneous tumour models do allow assessment of the efficacy of this approach in a solid tumour mass.
These data support the development of tumour suppresser gene therapy for pancreatic cancer and provide an important foundation for further pre-clinical studies. Specific targeting may be undertaken using tumourspecific promoters and regional arterial perfusion. 20 The use of p16 or p53 gene therapy should become a useful treatment approach and may enhance conventional chemotherapeutic approaches.
Materials and methods

Cell lines and cell culture
The human pancreatic cancer cell lines Panc1, Capan2, MIAPACA2, BxPc3 and CFPAC1 and 293 cells used for propagation of adenovirus were obtained from American Type Culture Collection (Rockville, MD, USA). All cells were cultured in DMEM (GIBCO, Paisley, UK) supplemented with 10% foetal calf serum (FCS), 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (Sigma, Poole, UK) except BxPc3 and CFPAC1 cells which were cultured in RPMI (GIBCO, UK) supplemented as above. The mutation status of the human pancreatic cancer cell lines is outlined in Table 4 .
Adenoviral vectors
Replication-deficient E1-deleted adenoviruses derived from Ad5 were used. The control vector AdlacZ contained the E. coli ␤-galactosidase gene driven by the cytomegalovirus promoter and Adluc contained the firefly luciferase gene driven by the Rous sarcoma virus promoter. The therapeutic vectors, Adp53 (aka RPR/INGN 201) and Adp16 contained human wild-type p53 and p16 cDNAs, respectively, under the control of a CMV promoter and an SV40 polyadenylation signal. Adenoviruses were propagated on 293 cell monolayers and harvested, aliquoted and stored as described. 37 Viral titre in plaqueforming units (p.f.u.) was determined by plaque assays on 293 cells; all MOIs are in p.f.u. per cell. Viral particle titres were determined spectrophotometrically, roughly. 38 
Transduction efficiency
Cell monolayers were infected with AdlacZ at a variety of MOIs, in 1 ml of medium in 25-cm 3 tissue culture flasks, under routine conditions. Twenty-four hours following infection cells were fixed in 96% ethanol and stained with X-gal solution. The percentage of positively stained cells was determined by scoring five random high power fields per 25-cm 3 flask. 
Immunofluorescence
Immunofluorescence was used to assess in situ expression of the therapeutic genes. Cells grown on coverslips were infected with vector at an MOI of 50-100 or with PBS as control. After 48 h, cells were fixed using 96% ethanol and permeabilised in 1 ml of 0.2% Triton. Cells were blocked using 50 l of DMEM (10% FCS) and incubated with 50 l of 1:100 dilution of monoclonal p16 antibody (Santa Cruz Biotechnology) or 1:100 p53 antibody (DO7; Dako) for 1 h. Cells were incubated with 50 l of anti-mouse IgM FITC (Vector Laboratories, Peterborough, UK) conjugate at 1:79 dilution for 45 min at 37°C, following which the coverslips were mounted using Vectorshield (Vector Laboratories) and visualised by confocal microscopy.
Cell growth curves
Cells were plated at a density of 10 5 per 25-cm 3 flask and infected with viral vectors at an MOI of 50 (100 for CFPAC1 and MIAPACA). Cells were harvested at the time of infection (time 0) and at 24, 48, 72, 120 and 168 h after infection. The number of viable cells was calculated using trypan blue exclusion. The experiment was performed in triplicate and the number of viable cells plotted against time. Mock infections used 1 ml PBS as a substitute for the vector. For all vector groups (including the combination groups) the number of viral particles of p53 or p16 was equivalent. The total number of viral particles delivered was kept constant by the addition of control vector to the single treatment groups.
Cell cycle analysis
The effect of adenoviral vectors on cell cycle dynamics was examined using flow cytometry. Cells were infected with virus at an MOI of 50-100 and harvested at time 0 and at 24, 48 and 72 h after infection. The cells were washed with PBS and treated with ice-cold 70% ethanol for 30 min. Cells were harvested and 100 l of RNase (1 mg/ml) and 100 l propidium iodide (400 g/ml) was added and left to incubate at 37°C for 30 min. Cells were analysed with a flow cytometer using an argon ion laser (Becton Dickinson FACScan, Rutherford, NJ, USA). The proportion of cells in each phase of the cell cycle was calculated for each time-point and vector. Cell debris and fixation artefacts were excluded by appropriate gating.
Gene Therapy
Apoptosis -TdT FragEL labelling The TdT Frag EL assay (Calbiochem, Nottingham, UK) was used to label exposed 3Ј-OH ends of DNA fragments. Cells were harvested at 0, 48 and 72 h following infection with virus vectors and fixed in 96% ethanol on to APES-coated glass slides using a Cytospin (Shandon Southern, Runcorn, UK). The cells were then labelled using TdT labelling reaction mix and TdT enzyme. The labelling reaction was terminated and detection accomplished using DAB. The number of apoptotic cells was counted per five high power fields per slide and calculated as a percentage of total cells.
Growth and treatment of subcutaneous tumours in nude mice Adenoviral vectors were assessed in vivo using subcutaneous tumours generated from the human pancreatic cancer cell line MIAPACA2 in nu-nu mice. Eight-weekold female athymic nu-nu mice were injected with 10 7 cells in 100 l serum-free DMEM into the subcutaneous tissue of each dorsal flank, to generate two subcutaneous tumours per animal. There were six mice with a total of 12 tumours in each experimental group. The tumours were left to develop for 8 weeks. Each tumour was then injected with a total of 10 11 virus particles daily over 3 consecutive days. Group 1 received Adluc, group 2 AdLacZ, group 3 Adp16, group 4 Adp53 and group 5 a combination of Adp16 and Adp53. The virus was injected using four needle passes, two perpendicular and two parallel to the axis of the tumour. Twenty-four hours following the last injection, one animal was killed and the tumours removed. Half of each tumour was snap-frozen in liquid nitrogen and the other half was fixed in 10% neutral-buffered formalin. The remaining mice in groups 1, 2, 3 and 4 were then maintained for up to 52 days at which point all mice were killed. The mice in group 5 were killed at 21 days following virus injection. Every 3 days the tumours were measured in two dimensions using callipers. The tumour volume was calculated using the equation: Tumour volume = /6 × longest diameter × shortest diameter. 2 The change in tumour volume was calculated as a ratio to determine the therapeutic effect of the vectors. All procedures were carried out according to UK Home Office regulations.
Expression of transduced genes in vivo
The tumours were snap-frozen in liquid nitrogen 24 h after the last of three virus injections. RNA was extracted using RNAzol B (Biogenesis, Poole, UK). cDNA was then generated using the cDNA Cycle Kit for RT-PCR (Invitrogen, San Diego, CA, USA). To assay expression of the p53 transgene of Adp53 primers were generated to amplify a 294 bp product which is specific for Adp53. The forward primer (5Ј GGTGCATTGGAACGCGGATT 3Ј) is in transcribed sequences derived from the CMV promoter, and the reverse primer (5Ј GGGGACA GAACGTTGTTTTC 3Ј) is in the p53 open reading frame spanning the exon 3-exon 4 junction. These primers do not detect endogenous p53 DNA or mRNA. Reaction conditions were 95°C for 5 min, then 35 cycles of 95°C for 1 min, 58°C for 1 min and 72°C for 1 min followed by 72°C for 5 min. For p16 PCR, oligonucleotides were generated to amplify a 360 bp fragment of the p16 INK4 gene. The forward primer was 5Ј CCCAACGCACCGAA TAGTTA 3Ј and the reverse primer was 5Ј TTCAATCGGGGA TGTCTGAG 3Ј (GIBCO BRL Custom Primers, Life Technologies, UK). For PCR there was a hot start without Taq at 99°C for 5 min. Taq was then added to the reaction mixture with 35 cycles of 95°C for 1 min, 60°C for 1 min and 72°C for 1 min followed by an extension of 72°C for 5 min. The PCR products were subjected to agarose gel electrophoresis. The DNA bands were visualised using ethidium bromide staining and UV illumination.
Statistics
The Mann-Whitney U non-parametric test was used on paired data and growth curves were compared using analysis of variance. Kaplan-Meier analysis was used for survival data. Significance was set at P Ͻ 0.05.
